Revenue Growth Driven by Volume and Rate
Total revenue grew 6.0% YoY from $3.22B to $3.42B in Q1 FY2026, reflecting continued patient volume growth and favorable reimbursement rate dynamics in DaVita's dialysis services business.
DAVITA INC. is expected to release its Q2 2026 10-Q filing in the upcoming earnings season. Last quarter: DaVita (DVA) delivered strong Q1 FY2026 results with revenue up 6.0% YoY to $3.42B and net income surging 21.2% to $197.5M, driven by improved operating leverage and significantly higher operating cash flow of $320.8M.
Drawn from management commentary in the Q1 2026 10-Q:
Total revenue grew 6.0% YoY from $3.22B to $3.42B in Q1 FY2026, reflecting continued patient volume growth and favorable reimbursement rate dynamics in DaVita's dialysis services business.
Operating margin improved approximately 50 basis points YoY to 14.1% (from 13.6%), with operating income rising 9.8% to $481.9M, indicating that revenue growth outpaced cost increases and the company achieved meaningful operating leverage.
Net income jumped 21.2% YoY to $197.5M, while diluted EPS surged 43.5% to $2.87 (from $2.00), with the outsized EPS gain relative to net income growth reflecting the impact of ongoing share repurchase activity reducing the share count.
Revenue
$3.42B
++5.96% YoY
EPS (Basic)
$2.93
++42.93% YoY
Operating Income
$481.89M
++9.79% YoY
Add DVA to your watchlist to get the AI analysis in your inbox within minutes of the 10-Q filing.